Project Grant R01CA307127
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $703K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Grant Award Summary New York University School of Medicine received a $681,215 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) beginning September 1, 2025 and concluding August 31, 2030. The project aims to develop artificial intelligence (AI)-enabled magnetic resonance (MR) imaging technology to support point-of-care prostate cancer detection at the population level. The research challenges conventional...
- Federal Grant Award Summary Cereus Diagnostics Corp. received a $764,448 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 1, 2025, with completion targeted for July 31, 2028. The company is developing LUNG-FAST (Fragment Analysis, SNP, and Translocations), a rapid polymerase chain reaction (PCR)-based diagnostic test designed to detect clinically actionable lung cancer mutations including EGFR, KRAS, ALK,...
- Federal Grant Award Summary New York University School of Medicine received a $585,482 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective June 1, 2026 through May 31, 2031. This five-year research award supports fundamental investigations into the molecular mechanisms of breast cancer metastasis, specifically examining the dual role of the translation factor DAP5 (Death-Associated Protein 5) in selective messenger RNA...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $270,683 to the New York Genome Center, Inc. under the Cancer Biology Research program (CFDA 93.396) on May 5, 2026, for development and validation of a novel single-cell multiomics sequencing technique. The project, which runs through April 30, 2029, centers on developing Paired-Break-Seq, a high-throughput method for joint analysis of DNA double-strand breaks (DSBs), single-strand breaks (SSBs), and transcriptome...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded New York University School of Medicine a $2,013,199 Project Grant effective September 1, 2025, through November 30, 2029, under the Cancer Treatment Research program (CFDA 93.395). This award supports the expansion of NCI-sponsored clinical research in hematologic malignancies to Brooklyn and Queens through the Perlmutter Cancer Center (PCC). The PCC will oversee a robust portfolio of clinical trials across national networks...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital a $2.86 million Project Grant under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on September 19, 2025, with completion targeted for August 31, 2029. The award funds development and validation of CAMPEX (CRISPR-Accelerated Molecular Profiling of Extracellular Vesicles), an innovative diagnostic platform designed to advance cancer detection and monitoring through liquid...
- Federal Grant Award Summary The National Cancer Institute awarded Harvard Medical School a $237,023 Project Grant under the Cancer Biology Research program (CFDA 93.396) beginning March 13, 2026, with completion targeted for February 28, 2029. This award supports the development and application of high-throughput tools designed to track the fate of prematurely terminated transcripts in cancer cells, specifically focusing on alternative polyadenylation (APA) events that drive oncogenic mechanisms...
- Federal Grant Award Summary The University of Washington received a $369,468 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) for research on efficient, cost-effective, and ultrasensitive sequencing of somatic mutations and methylation. The award, effective September 1, 2025, through August 31, 2028, supports the development of next-generation sequencing (NGS) technologies capable of detecting and quantitating genetic and...
- Federal Project Grant Award Summary The University of Connecticut Health Center received a $414,585 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded on May 6, 2026, with an ultimate completion date of April 30, 2029. The grant supports the development and validation of a programmable enzyme-assisted mutation sequencing (PEAM-SEQ) diagnostic platform designed to detect multiple cell-free DNA (cfDNA) mutations...